passage bio stock forecast

This biotech has a lead gene therapy program that is. PASG stock analyst estimates including earnings and revenue EPS upgrades and downgrades.

Pasg Passage Bio Inc Stock Price Forecast Ticker Score

Find real-time PASG - Passage Bio Inc stock quotes company profile news and forecasts from CNN Business.

. Analyst estimates including PASG earnings per share estimates and analyst recommendations. In addition Passage Bio has granted the underwriters a 30-day option to purchase up to an additional 1050000. BIO Stock Trend.

Jan 6 2022 219AM EST. Passage Bio NASDAQPASG Get Rating last posted its quarterly earnings data on. The Company is focused on developing transformative therapies for central nervous system CNS disorders.

The stock is currently down 750 year-to. The firm is a pre-clinical biopharma working on monogenic. That PASSAGE BIOs share price could reach 1833 by Mar 8 2023.

Shares of NASDAQPASG opened at 295 on Friday. The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Stocks and Shares ISA Lifetime ISA SIPP Fund and Share Account.

Passage Bio has a fifty-two week low of 281 and a fifty-two week high of 2212. 913a Nikola stock rises after narrower-than. Has a 52-week low of 257 and a 52-week high of 2212.

PHILADELPHIA March 15 2022 GLOBE NEWSWIRE -- Passage Bio Inc. Given the current short-term trend the stock is expected to fall -2007 during the next 3 months and with a 90 probability hold a price between 39351 and 48941 at the end of this 3-month period. PASG Passage Bio Inc.

PASG stock quote history news and other vital information to help you with your stock trading and investing. Its first product candidate PBGM01 utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase ÃŸ. Passage Bio NASDAQPASG intends to raise 125 million in an IPO.

Estimated cash runway extended into Q2 2024. Passage Bio a Philadelphia-based gene therapy developer will cut jobs and pare back spending in an effort to save cash and focus resources on three experimental treatments currently in clinical testing. Passage Bio Inc PASG shares closed today at 10 above its 52 week low of 630 giving the company a market cap of 346M.

All shares of common stock to be sold in the offering will be sold by Passage Bio. PASG a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system CNS disorders today provided an update on strategic priorities to extend its cash runway. Dec 30 2021 403AM EST.

This stock can be held in a. If you are looking for stocks with good return Passage Bio Inc stock can be a bad high-risk 1-year investment option. The stock is currently down 28 year.

Passage Bio has been rated by Chardan Capital JPMorgan Chase Co. Passage Bio Inc real time quote is equal to 3950 USD at 2022-02-17 but your current investment may be devalued in the future. 020 897 Deal for just 1195 per trade in a.

What analysts cover Passage Bio. The stocks fifty day simple moving average is 444 and its 200-day. On average Wall Street analysts predict.

Summary of all time highs changes and price drops for Passage Bio. Find the latest Passage Bio Inc. Passage Bio has filed to raise 126 million in an IPO of its common stock.

The average PASSAGE BIO stock price prediction forecasts a potential upside of 49139 from the current PASG share price of 310. See Passage Bio Inc. This is according to an S-1 registration statement filed with the SEC.

Is a clinical stage genetic medicines company. According to analysts Passage Bios stock has a predicted upside of 29801 based on their 12-month price targets. The restructuring announced on Tuesday will reduce Passages workforce by 13 or by between 15 to 20 employees according to a company.

Passage Bio Inc PASG shares closed 36 lower than its previous 52 week low giving the company a market cap of 333M. Bruce Goldsmith Courtesy Passage Bio Passages stock jumped 20 on Friday its first day trading from 18 to nearly 22. Please note that any opinions estimates or forecasts regarding Passage Bio Incs performance made by these analysts are theirs alone and do not represent opinions forecasts or predictions of Passage Bio.

Is followed by the analysts listed above. Raymond James and Wedbush in. Passage Bio undertakes no obligation to publicly update any forward-looking statement whether written or oral that may be made from time to time whether as a result of new information future.

What Type Of Shareholders Make Up Passage Bio Inc S Nasdaq Pasg Share Registry

Ipo Update Passage Bio Finalizes 126 Million Ipo Plan Nasdaq Pasg Seeking Alpha

Time To Go Bottom Fishing These 3 Strong Buy Stocks Are On Sale Nasdaq

Passage Bio Stock Forecast Down To 0 000001 Usd Pasg Stock Price Prediction Long Term Short Term Share Revenue Prognosis With Smart Technical Analysis